TSHA Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. (TSHA) is expected to report earnings on February 11, 2027, before the market open. The consensus earnings estimate is a loss of $0.10 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.1% since its last earnings release on November 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease.
Sector
Healthcare
Industry
Biotechnology
Held By 2 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.